All In Biotech

Drug Trial Radar · NCT04180215

A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers

Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

198

Actual

Start

Dec 11, 2019

Primary completion

Jan 9, 2025

Study completion Jan 9, 2025

Sponsor

Lead sponsor
Hookipa Biotech GmbHIndustry
Sponsor type
Industry
First posted
Nov 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a First in Human (FIH) Phase I/II, multinational, multicenter, open-label study of HB-201 single vector therapy and HB-201 \& HB-202 two-vector therapy in patients with HPV 16+ confirmed cancers comprising two parts: Phase I Dose Escalation and Phase II Dose Expansion.

Conditions

  • HPV-Related Squamous Cell Carcinoma

Interventions

  • HB-201 intravenous administration.Drug

    Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).

  • HB-202 intravenous administration alternating with HB-201 intravenous administration.Drug

    Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).

  • HB-201 intravenous administration + standard of care regimen including pembrolizumab.Drug

    Dose Expansion

  • HB-202 / HB-201 alternating intravenous administration + pembrolizumab.Drug

    Dose Expansion

  • HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.Drug

    Dose Expansion

  • HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)Drug

    Dose escalation; 10 patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I Dose Escalation: Determine Phase II dose based on incidence of dose-limiting toxicities.Time frame: From dosing until 21-28 days after first dose
  2. Phase II Dose Expansion: Number of participants with preliminary antitumor activity based on objective response rate.Time frame: Until progression, (estimated up to 30-months)

Locations

34 sites in 3 countries. Site status is shown where the registry gives one.

  • O'Neal Comprehensive Cancer Center at UAB

    Birmingham, Alabama

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • University of Arkansas for Medical Sciences, Cancer Institute, Clinical Trials Office

    Fayetteville, Arkansas

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA (University of California, Los Angeles)

    Los Angeles, California

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • University of Chicago Medical Center

    Chicago, Illinois

  • Loyola University Medical School

    Maywood, Illinois

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa

  • University of Kansas Medical Center

    Fairway, Kansas

  • Henry Ford Hospital

    Detroit, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • Grossman School of Medicine

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Perlmutter Cancer Center at NYU Langone Hospital-Long Island

    New York, New York

  • Montefiore-Einstein Center for Cancer Care

    The Bronx, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • Providence Portland Medical Center

    Portland, Oregon

  • Greenville Hospital System University Medical Center (ITOR)

    Greenville, South Carolina

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Virgina Health System

    Charlottesville, Virginia

  • Froedtert Hospital and Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Amsterdam UMC, Locatie VUMC

    Amsterdam, Netherlands

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain

  • Centro Integral Oncologico Clara Campal

    Madrid, Spain

  • Hospital Universitario Virgen Macarena

    Seville, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.